ClinicalTrials.gg
RecruitingNCT07290517CAREUpdated Aug 13, 2026

Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

An interventional study of Carevix and Tenaculum in IUD, Abnormal Uterine Bleeding and Pain, Cervical, sponsored by Indiana University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Indiana University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Metrorrhagia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Metrorrhagia · United States.

Planned enrollment
10th of 40
100 · median 60
Started
2026
with 5 others
No phase
23 of 43
4 open now
Registered
39th of 43
by date
Lead sponsor
3 of 43
Indiana University

Among the 43 studies in Metrorrhagia with a site in United States, this one is the 10th largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 23 with no phase, and was the 39th registered.

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 34 are open to participants now.

Browse Metrorrhagia studies →

Open to participants now

8 of the 43 studies in Metrorrhagia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Metrorrhagia studies recruiting now, 10 (50%) set no upper age limit and 10 (50%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Metrorrhagia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between IUD insertions using a suction cervical stabilizer (new device, FDA approved, atraumatic) and single-tooth tenaculum (standard, traumatic). Our aims are to:

  • assess and compare patient-reported pain during IUD insertion between the Carevix device and tenaculum.
  • assess predictors of pain scores including between nulliparous and multiparous patients
  • assess provider-reported ease of use and satisfaction

Participants (including providers) will:

  • be randomized to receive one device to complete the IUD procedure
  • complete a survey following the procedure
Read the detailed description

The primary objective is to assess and compare patient-reported pain during IUD insertion between the Carevix device and tenaculum. The hypothesis is that patient-reported pain scores comparing Carevix™ to tenaculum will be lower. The investigators will assess pain, and predictors for pain scores including nulliparous vs multiparous, when highest pain scores are reported, and expectation of pain for the procedure.

The secondary objective will be to assess Usability (provider assessment of ease of use, number of device placement attempts to secure sufficient traction on uterus), efficacy (ability to insert IUD with Carevix™ device alone without recourse to conventional tenaculum or other instruments), provider reported bleeding (cervical bleeding and ecchymosis), overall provider satisfaction, patient-reported pain scores at device placement prior to IUD insertion procedure and after completion of IUD insertion using Visual Analog Scale (VAS), overall patient satisfaction, and overall provider satisfaction. The investigators aim to expand the pilot trial data collection to assess cultural background, ethnicity and demographics while also assessing prior contraceptive choices, reasons for discontinuation of prior choices and reasons for current selection of IUD insertion and any anticipated barriers for removal.

03

Conditions studied

  • IUD
  • Abnormal Uterine Bleeding
  • Pain, Cervical

Keywords

  • IUD insertion
  • Cervical Stabilization
  • Tenaculum
  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (to be assessed prior to procedure):

  • Age 18 years or older
  • Able to consent on their own
  • Scheduled and will undergo an IUD insertion within 90 days of consent
  • Planned use of cervical stabilization device for placement
  • Procedure being performed by a trained provider
  • Provider is willing to use Carevix™ for scheduled procedure

Exclusion Criteria (to be assessed by provider at time of procedure):

  • Vaginal bleeding of unknown origin
  • Cervix less than 26 mm in diameter
  • Nabothian cyst on anterior lip of cervix
  • Cervical myomas
  • Cervical abnormalities/shape
  • Pregnant
  • Participants who are not fluent in and/or do not fully understand, read, write, or speak the English language
  • Other inability to provide to participate
  • Initial attempt to place the IUD without any cervical stabilization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Carevix

    Patients will receive the atraumatic, suction-based, cervical stabilizer (Carevix) for their IUD insertion.

    Device: Carevix

  • Active comparator
    Tenaculum

    Patients will receive the standard of care device (single tooth tenaculum) for their IUD insertion.

    Device: Tenaculum

Interventions

  • DeviceCarevix

    Vacuum cervical stabilization device

  • DeviceTenaculum

    Standard of care cervical stabilization device

06

What researchers measure

Primary outcomes

  1. Patient pain score

    Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: During Procedure (at Cervix Grasping, at Cervix Traction, and at IUD placement)

  2. Difference in Pain Score

    Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable." Pain scores will be compared among nulliparous and multiparous participants

    Time frame: Prior to procedure, during procedure (at cervix grasping, at cervix traction, at IUD placement), and 5 minutes after procedure completion

  3. Highest Pain Score

    Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable." The time at which the highest pain score was reported will be compared.

    Time frame: Prior to procedure, during procedure (at cervix grasping, at cervix traction, at IUD placement), and 5 minutes after procedure completion

  4. Expectation of Pain

    Participants will be asked to rate their expectation of pain on a scale of 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: Within 15 minutes after IUD procedure completion

Secondary outcomes

  1. Provider device satisfaction - Time to Use Device

    Providers will be asked to provide their agreement that procedure time was not extended due to the device use on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"

    Time frame: Immediately after IUD procedure

  2. Provider device satisfaction - Impact on Patient Discomfort

    Providers will be asked whether the device's use impacted patient discomfort on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree."

    Time frame: Immediately after IUD insertion procedure

  3. Provider device satisfaction - Device Preference

    Providers will be asked to rate their overall satisfaction with the device on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"

    Time frame: Immediately after IUD insertion procedure

  4. Provider device satisfaction - Procedure Visibility

    Providers will be asked to rate visibility while using the device on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"

    Time frame: Immediately after IUD insertion procedure

  5. Provider device satisfaction - Pulling Strength

    Providers will be asked to rate the device's pulling strength as adequate on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"

    Time frame: Immediately after IUD insertion procedure

  6. Provider device satisfaction (Ease of Use)

    Providers using the Carevix device will be asked to rate ease of use on a 5 point Likert scale from "Strongly Disagree"-"Strongly Agree."

    Time frame: Immediately after IUD procedure

  7. Number of Device Placement Attempts

    Providers are asked to report the number of attempts required for device placement

    Time frame: Immediately after IUD insertion procedure

  8. Need for Device Replacement

    Providers who use the Carevix device will be asked if the procedure's successful completion required replacing the Carevix device with the cervical tenaculum

    Time frame: Immediately after IUD insertion procedure

  9. Provider Reported Bleeding

    The number of providers who had to manage or stop bleeding on cervical tissues will be compared.

    Time frame: Immediately after IUD insertion procedure

  10. Time to Bleeding Cessation

    The time (minutes) required for the providers to stop bleeding of cervical tissues will be compared.

    Time frame: Immediately after IUD procedure completion

  11. Patient pain score

    Participants will be asked to rate their pain prior to, during, and after the IUD insertion procedure on a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable."

    Time frame: Prior to Procedure and 5 minutes after procedure completion

  12. Overall Patient Satisfaction

    Participants will rate their satisfaction with the procedure on a 5 point Likert scale from 5 point Likert scale from "Strongly Disagree"-"Strongly Agree"

    Time frame: Immediately after IUD procedure completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yaron M, Legardeur H, Barcellini B, Akhoundova F, Mathevet P. Safety and efficacy of a suction cervical stabilizer for intrauterine contraceptive device insertion: Results from a randomized, controlled study. Contraception. 2023 Jul;123:110004. doi: 10.1016/j.contraception.2023.110004. Epub 2023 Mar 11. PubMed 36914147 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 41 non-industry interventional studies with no phase under Metrorrhagia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 43 studies reached it within 17 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 18, 2025
StartActual
Mar 11, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290517
Lead sponsor
Indiana University
Collaborators
Aspivix SA
Responsible party
Alissa M Conklin (Assistant Professor of Clinical Obstetrics and Gynecology, Indiana University) — Principal investigator
First posted
Dec 18, 2025
Start date
Mar 11, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Alissa M Conklin, MD
Contact
alconkli@iu.edu
317-944-8231
Kylie L Williams, MA
Contact
kylowill@iu.edu
Alissa M Conklin, MD
principal investigator · Indiana School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion